Home » Find Clinical Trials
190 Results
Protocol Code
Study Title
Active substance/Medical device
Study Phase
Therapeutic Area
CL2-20098-072
Efficacy of agomelatine 25 mg/day (with possible increase to 50 mg/day after 8 weeks of…
AGOMELATINE, S020098
Phase 2
Neuropsychiatric Diseases
CL2-20098-067
Effect of agomelatine (25 mg) given orally once a day for 7 days on cerebral…
AGOMELATINE, S020098
Phase 2
Neuropsychiatric Diseases
CL2-20098-040
Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally…
AGOMELATINE, S020098
Phase 2
Neuropsychiatric Diseases
CL2-18986-009
Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild…
S018986
Phase 2
Neuropsychiatric Diseases
CL2-18886-031
Effects of S 18886 on platelet function in type 2 diabetic patients treated by low-dose…
TERUTROBAN, S018886
Phase 2
Metabolism
CL2-18886-026
Effects of terutroban versus aspirin on composition of atherosclerotic plaque in patients undergoing a carotid…
TERUTROBAN, S018886
Phase 2
Cardiovascular Diseases
CL2-16257-101
Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients…
IVABRADINE, S016257
Phase 2
Cardiovascular Diseases
CL2-16257-099
Effects of ivabradine on vascular function in individuals at increased risk of developing cardiovascular disease…
IVABRADINE, S016257
Phase 2
Cardiovascular Diseases
CL2-16257-096
Effects of oral chronic administration of ivabradine (7.5 mg bid) in comparison to placebo (bid)…
IVABRADINE, S016257
Phase 2
Cardiovascular Diseases
CL2-16257-095
Effects of oral administration of ivabradine (7.5 mg bid) on post-ischaemic stunning induced by exercise…
IVABRADINE, S016257
Phase 2
Cardiovascular Diseases
CL2-16257-090
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy…
IVABRADINE, S016257
Phase 2
Cardiovascular Diseases
CL2-16257-088
Effects of ivabradine IV versus placebo on haemodynamic parameters in patients with a low cardiac…
IVABRADINE, S016257
Phase 2
Cardiovascular Diseases
CL2-16257-073
Evaluation of the effects of oral administration of ivabradine 5 mg and 7.5 mg b.i.d.…
IVABRADINE, S016257
Phase 2
Cardiovascular Diseases
CL2-16257-062
Evaluation of the effects of 3 successive oral dosages (2.5, 5, 7.5 mg b.i.d.) of…
IVABRADINE, S016257
Phase 2
Cardiovascular Diseases
CL2-16257-060
Evaluation of the effects on heart rate, haemodynamic parameters, safety and tolerability of 5 mg…
IVABRADINE, S016257
Phase 2
Cardiovascular Diseases
CL2-16257-053
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
IVABRADINE, S016257
Phase 2
Cardiovascular Diseases
CL2-12911-039
A double-blind, multicenter, international randomised study to assess the effects of 4 month-oral administration of…
STRONTIUM RANELATE, S012911
Phase 2
Rheumatology
CL2-09490-157
Assessment of the effects on 24-hour ambulatory blood pressure and the safety of a once-a-day…
PERINDOPRIL TERT BUTYLAMINE, S009490
Phase 2
Cardiovascular Diseases
CL2-066913-002
A randomized, double blind, placebo-controlled, parallel, international multicenter study assessing the efficacy of S066913 in…
S066913
Phase 2
Cardiovascular Diseases
CL2-05985-005
Efficacy and safety of the fixed oral low-dose perindopril arginine 3.5 mg/amlodipine 2.5 mg combination…
AMLODIPINE, PERINDOPRIL ARGININE, S005985
Phase 2
Cardiovascular Diseases
CL2-05720-005
Efficacy and safety assessment of two schemes of oral administration of once-daily extended release metformin…
GLICLAZIDE, METFORMINE, S005720
Phase 2
Metabolism
CL2-05682-102
Impact of Daflon 500 mg on the progression of chronic venous disease and symptoms in…
MICRONISED PURIFIED FLAVONOID FRACTION, S005682
Phase 2
Cardiovascular Diseases
CL2-05682-099
Effects of micronised purified flavonoic fraction on microcirculation in women suffering from chronic venous disease
MICRONISED PURIFIED FLAVONOID FRACTION, S005682
Phase 2
Cardiovascular Diseases
CL1-95005-001
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer
TIPIRACIL, TRIFLURIDINE, S095005
Phase 1
Cancers
CL1-81694-001
Phase I dose-escalation study of S 81694 administered intravenously in adult patients with advanced/metastatic solid…
S081694
Phase 1
Cancers
Servier clinical trials are mainly registered on
EU Clinical Trials Register
The EU Clinical Trials Register contains information on interventional clinical trials on medicines conducted in Europe, which started after 1 May 2004.
SEE MORE
ClinicalTrials.gov
Clinicaltrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.
SEE MORE
ISRCTN registry
The ISRCTN registry is a primary clinical trial registry recognised by WHO and ICMJE that accepts all clinical research studies.
SEE MORE
© 2021 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.